- $358.21bn
- $405.02bn
- $65.01bn
US drug lobby group names former House leader Cantor as CEO (updated)
US drug lobby group PhRMA names former House leader Cantor as CEO
Factbox: Pharma sector doubles down on AI to slash costs, timelines
US RESEARCH ROUNDUP-Acuity, Dell Technologies, Nike
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion (updated)
Factbox: US drugmakers turn to China for licensing deals
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion
Brief: Merck Enters Exclusive Global License Deal With Scibrunch Therapeutics For SPR2015
Brief: Merck Enters Into Exclusive Global License Agreement With Scibrunch Therapeutics For Spr2015, An Investigational Oral Kras G12d (On) Inhibitor
Brief: Ifinatamab Deruxtecan Biologics License Application For Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
Merck, Daiichi pull US application for second partnered cancer therapy (updated)
Merck, Daiichi Sankyo withdraw US application for lung cancer drug
Brief: U.S. FDA Approves Welireg Plus Lenvima For Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With A Clear Cell Component
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Merck's drug for diabetes-related eye disease meets trial goal (updated)
Merck's eye disease drug meets main goal in trial
Brief: Merck’S Remigromig, A Tri-Specific Agonist Of The Wingless-Related Integration Site Pathway, Met Primary Endpoint In The Pivotal Phase 2B/3 Brunello Study Of Adults With Diabetic Macular Edema
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up